Research

Hormonal

GLP-1 receptor agonists (GLP1RAs) and SGLT2 inhibitors should be used as first-line treatment in patients with Type 2 Diabetes and initial kidney disease, combined with Metformin.

If you have Type 2 Diabetes and early signs of kidney disease (like high blood pressure or protein in urine), ask your doctor about starting Metformin along with an SGLT2 inhibitor (like Jardiance or Farxiga). If more treatment is needed, a GLP-1 receptor agonist (like Ozempic or Trulicity) can be added. This combination is now recommended as the best way to protect your kidneys and heart.

StrongSupportsVERY_HIGH confidence
recent American Diabetes Association (ADA)/ Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend combining Metformin with an SGLT2-i as first-line treatment in people with T2DM and initial kidney disease, with GLP1-RA being added in case of need of treatment intensification [33].
Mahmoud Ibrahim et al. · Diabetes/Metabolism Research and Reviews · 2023

Why this rating

Based on recent ADA/KDIGO guidelines and multiple CVOTs showing renal benefits.

Source

Cardio‐renal‐metabolic disease in primary care setting

Mahmoud Ibrahim et al. · Diabetes/Metabolism Research and Reviews · 2023

narrative_reviewCited 11×
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →